Evidence map›Paper›PMID 33555020›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2021

Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference.

Larissa Fabritz, Harry J G M Crijns, Eduard Guasch, Andreas Goette, Karl Georg Häusler, Dipak Kotecha, Thorsten Lewalter, Christian Meyer, Tatjana S Potpara, Michiel Rienstra and 48 more

Open access · bronzeAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Timing of stroke risk reassessment in atrial fibrillation patients with a CHA2DS2-VA score of 0 or 1: the Norwegian AFNOR study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  11. Review
  12. Observational
  13. Article
  14. Review
  15. Article
  16. The Ablate-by-LAWT multicentre prospective study: Personalized paroxysmal atrial fibrillation ablation with ablation index adapted to local left atrial wall thickness.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024
    Article
  17. Review
  18. Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
  19. Review
  20. Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

58 authors at 20 institutions in 13 countries.

Larissa FabritzInstitute of Cardiovascular Sciences, University of Birmingham, UK.
Harry J G M CrijnsSchool for Cardiovascular Diseases, Maastricht University Medical Centre, the Netherlands.
Eduard GuaschHospital Clinic, IDIBAPS, CIBERCV, University of Barcelona, Spain.
Andreas GoetteMedical Clinic II, St. Vincenz Krankenhaus, Paderborn, Germany.
Karl Georg HäuslerDepartment of Neurology, University Hospital Würzburg, Germany.
Dipak KotechaInstitute of Cardiovascular Sciences, University of Birmingham, UK.
Thorsten LewalterAtrial Fibrillation NETwork (AFNET), Münster, Germany.
Christian MeyerUniversity Heart Center, University Hospital Hamburg-Eppendorf, Germany.
Tatjana S PotparaSchool of Medicine, University of Belgrade, Clinical Centre of Serbia, Serbia.
Michiel RienstraUniversity Medical Center Groningen, the Netherlands.
Renate B SchnabelAtrial Fibrillation NETwork (AFNET), Münster, Germany.
Stephan WillemsAtrial Fibrillation NETwork (AFNET), Münster, Germany.
Guenter BreithardtAtrial Fibrillation NETwork (AFNET), Münster, Germany.
A John CammSt George's Hospital Medical School, University of London, UK.
Anthony ChanPfizer.
Winnie ChuaInstitute of Cardiovascular Sciences, University of Birmingham, UK.
Mirko de MelisMedtronic.
Christina DimopoulouEuropean Society of Cardiology.
Dobromir DobrevDepartment of Cardiology, University Hospital Essen, Germany.
Christina EasterInstitute of Cardiovascular Sciences, University of Birmingham, UK.
Lars EckardtAtrial Fibrillation NETwork (AFNET), Münster, Germany.
Doreen HaaseAtrial Fibrillation NETwork (AFNET), Münster, Germany.
Stephane HatemDepartment of Cardiology, Sorbonne Universités, Faculté de médecine UPMC, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Jeff S HealeyPopulation Health Research Institute Hamilton, Canada.
Jordi HeijmanDepartment of Cardiology, University Hospital Birmingham, UK.
Stefan H HohnloserDepartment of Cardiology, Goethe-University of Frankfurt, Germany.
Thomas HuebnerPreventicus, Germany.
Bushra Saeed IlyasPfizer.
Aaron IsaacsSchool for Cardiovascular Diseases, Maastricht University Medical Centre, the Netherlands.
Ingo KutschkaAtrial Fibrillation NETwork (AFNET), Münster, Germany.
Christophe LeclercqUniv Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, F-35000 Rennes, France.
Gregory Y H LipLiverpool Centre for Cardiovascular Science, University of Liverpool, UK.
Elena Andreassi MarinelliDaiichi Sankyo Europe.
Jose L MerinoArrhythmia & Robotic EP Unit, La Paz University Hospital, Spain.
Lluís MontHospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
Michael NabauerAtrial Fibrillation NETwork (AFNET), Münster, Germany.
Jonas OldgrenDepartment of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Sweden.
Helmut PürerfellnerDepartment für Rhythmologie und Elektrophysiologie, Ordensklinikum Linz, Austria.
Ursula RavensAtrial Fibrillation NETwork (AFNET), Münster, Germany.
Irina SavelievaSt. George's University of London, UK.
Moritz F SinnerMedizinische Klinik und Poliklinik I, University Hospital Munich, Germany.
Alice SitchInstitute of Cardiovascular Sciences, University of Birmingham, UK.
Rüdiger SmolnikDaiichi Sankyo Europe.
Jan SteffelUniversity Heart Center Zurich, Switzerland.
Kenneth SteinBoston Scientific, USA.
Monika StollSchool for Cardiovascular Diseases, Maastricht University Medical Centre, the Netherlands.
Emma SvennbergDivision of Cardiovascular Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd's Hospital Stockholm, Sweden.
Dierk ThomasAtrial Fibrillation NETwork (AFNET), Münster, Germany.
Isabelle C Van GelderDepartment of Cardiology, University Medical Center Groningen, University of Groningen, the Netherlands.
Burcu VardarBayer Healthcare, Belgium.
Reza WakiliAtrial Fibrillation NETwork (AFNET), Münster, Germany.
Mattias WielochSanofi, Paris, France.
Stef ZeemeringDepartment of Cardiology, University Medical Center Groningen, University of Groningen, the Netherlands.
Paul D ZieglerMedtronic.
Hein HeidbuchelDepartment of Cardiology, Antwerp University, University Hospital, Belgium.
Gerhard HindricksDepartment of Electrophysiology, Heart Center Leipzig, University of Leipzig, Germany.
Ulrich SchottenSchool for Cardiovascular Diseases, Maastricht University Medical Centre, the Netherlands.
Paulus KirchhofInstitute of Cardiovascular Sciences, University of Birmingham, UK.
Atrial Fibrillation NETwork · DEUniversity Medical Center Groningen · NLUniversity of Birmingham · GBMaastricht University Medical Centre · NLUniversität Hamburg · DEDaiichi-Sankyo (South Korea) · KRLMU Klinikum · DEMedtronic (Ireland) · IENIHR Surgical Reconstruction and Microbiology Research Centre · GBPfizer (United States) · USUniversity Hospital Münster · DEAntwerp University Hospital · BEBayer (Belgium) · BEBoston Scientific (United States) · USCentro de Investigación en Red en Enfermedades Cardiovasculares · ESDanderyds sjukhus · SEEssen University Hospital · DEEuropean Society of Cardiology · FRGoethe University Frankfurt · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe risk of developing atrial fibrillation (AF) and its complications continues to increase, despite good progress in preventing AF-related strokes. METHODS AND

resultsThis article summarizes the outcomes of the 7th Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA) held in Lisbon in March 2019. Sixty-five international AF specialists met to present new data and find consensus on pressing issues in AF prevention, management and future research to improve care for patients with AF and prevent AF-related complications. This article is the main outcome of an interactive, iterative discussion between breakout specialist groups and the meeting plenary. AF patients have dynamic risk profiles requiring repeated assessment and risk-based therapy stratification to optimize quality of care. Interrogation of deeply phenotyped datasets with outcomes will lead to a better understanding of the cardiac and systemic effects of AF, interacting with comorbidities and predisposing factors, enabling stratified therapy. New proposals include an algorithm for the acute management of patients with AF and heart failure, a call for a refined, data-driven assessment of stroke risk, suggestions for anticoagulation use in special populations, and a call for rhythm control therapy selection based on risk of AF recurrence.

conclusionThe remaining morbidity and mortality in patients with AF needs better characterization. Likely drivers of the remaining AF-related problems are AF burden, potentially treatable by rhythm control therapy, and concomitant conditions, potentially treatable by treating these conditions. Identifying the drivers of AF-related complications holds promise for stratified therapy.

Indexed as

Atrial FibrillationStrokeAnticoagulantsHumansRisk AssessmentRisk FactorsTreatment OutcomeAnticoagulantsAFNETAnticoagulationAtrial cardiomyopathyAtrial fibrillationBig dataBleedingCatheter ablationCognitive functionConsensus statementEHRAHeart failureIntegrated careLifestyleOutcomesQuality of careRate controlResearchResearch prioritiesRhythm controlScreeningStrokeTechnology

Identifiers

PMID33555020
PMCPMC13453135
OpenAlexW3126263844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.